In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Altimmune (ALT – Research Report). The company’s shares ...

In a report released today, Myles Minter from William Blair reiterated a Buy rating on Intellia Therapeutics (NTLA – Research Report). The ...

Equities research analysts at William Blair lifted their Q1 2025 earnings estimates for HealthStream in a research note issued on Tuesday, February 25th. William Blair analyst R. Daniels now forecasts ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Analysts at William Blair upped their FY2025 EPS estimates for Straumann in a report issued on Monday, February 24th. William Blair analyst B. Vazquez now forecasts that the company will post earnings ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The new fund will invest in a niche subset of emerging markets that are 'more challenging for investors to access' ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Pediatrix Medical reported Q4 revenue of $502.36 million, surpassing estimates, with adjusted EPS of $0.51. The company ...